Press release
Jul 3, 2009

Sosei Announces Enrolment of First Patient in Phase III Clinical Study with NVA237

Tokyo, Japan – 3 July 2009: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) announces that the first patient has been enrolled in Novartis Phase III clinical study for NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of activity. The enrolment of the first patient triggered a $7.5 million milestone payment.